ALGS Aligos Therapeutics

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that management will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium 2024 being held in Boston, Massachusetts on April 16-17, 2024.

Please contact your Piper Sandler representative to schedule a one-on-one meeting.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best-in-class therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

Company

Jordyn Tarazi

Vice President, Investor Relations & Corporate Communications

(650) 910-0427

Media

Michael Fitzhugh

LifeSci Communications

(628) 234-3889



EN
09/04/2024

Underlying

ALGSAligos Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aligos Therapeutics

 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on ...

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company fo...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Presents Positive Data at the Conference on Retrov...

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado. The pevifoscorvir sodium presentation highlights the P...

February 23, 2026 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on Jan...

January 30, 2026 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates Interim analyses on track for the first and second half of 2026 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection. “2026 is an important year for Aligos as we continue to make...

January 21, 2026 1 EN
 PRESS RELEASE
Free
ALGS Aligos Therapeu...

Aligos Therapeutics Strengthens Senior Leadership Team with the Appoin...

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer Seasoned leader with global commercialization and marketing expertise SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective...

January 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch